My ePortfolio Register   

ESMO 2017 /
PACIFIC trial of durvalumab for lung cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 200
Rating:

Dr Luis Paz-Ares - Hospital Universitario Doce de Octubre, Madrid, Spain

Dr Luis Paz-Ares presents in a press conference at ESMO 2017 data from the double blind phase III PACIFIC trial of durvalumab as sequential treatment in patients with locally-advanced, unresectable lung cancer. 

Dr Paz-Ares states that durvalumab yielded a median progressive free survival rate of 16.8 months, compared to 5.6 months for patients on the placebo, with overall survival yet to mature.

Read the news story for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence